Zobrazeno 1 - 10
of 42
pro vyhledávání: '"KATSUAKI CHIKUI"'
Autor:
Kosuke Ueda, Keiichiro Uemura, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Sachiko Ogasawara, Hirohisa Yano, Tsukasa Igawa
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1701-1712 (2024)
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the exp
Externí odkaz:
https://doaj.org/article/11f53d13330b4e1285ae6a5190539e9a
Autor:
Yuko Matsuo, Kenji Ashida, Ayako Nagayama, Kanoko Moritaka, Mizuki Gobaru, Junichi Yasuda, Naoyuki Ogasawara, Hirofumi Kurose, Katsuaki Chikui, Shimpei Iwata, Yukihiro Inoguchi, Nao Hasuzawa, Seiichi Motomura, Tsukasa Igawa, Masatoshi Nomura
Publikováno v:
Endocrine Oncology, Vol 3, Iss 1, Pp 1-12 (2023)
Objective: Metyrosine (alpha-methyl-para-tyrosine) effectively reduces catecholamine levels in patients with pheochromocytoma/paraganglioma. However, improvements in physiological and metabolic parameters and changes in endocrine function associated
Externí odkaz:
https://doaj.org/article/f6e2c7d598b54590b724575d8e6a4b40
Autor:
Makoto Nakiri, Naoyuki Ogasawara, Hirofumi Kurose, Kosuke Ueda, Katsuaki Chikui, Kiyoaki Nishihara, Kazuhisa Ejima, Keiichiro Uemura, Kenta Murotani, Koichiro Muraki, Chikayuki Hattori, Etsuyo Ogo, Yoshitaka Morimatsu, Tatsuya Ishitake, Tsukasa Igawa
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 14, Iss 2, Pp 157-168 (2022)
Externí odkaz:
https://doaj.org/article/15782f7123944fda9ab40fe834136839
Autor:
Koichiro Muraki, Chikayuki Hattori, Etsuyo Ogo, Hiroaki Suefuji, Hidehiro Eto, Chiyoko Tsuji, Yusaku Miyata, Toshi Abe, Katsuaki Chikui, Makoto Nakiri, Tsukasa Igawa, Tatsuyuki Kakuma
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 13, Iss 3, Pp 254-262 (2021)
Externí odkaz:
https://doaj.org/article/4b01ac62a64341d39879ae27300b79fb
Autor:
Hirofumi Kurose, Kosuke Ueda, Mami Uegaki, Naoyuki Ogasawara, Hisaji Kumagae, Katsuaki Chikui, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo, Shigetaka Suekane, Jun Akiba, Hirohisa Yano, Tsukasa Igawa
Publikováno v:
IJU Case Reports, Vol 3, Iss 5, Pp 192-195 (2020)
Introduction Paraganglioma of the urinary bladder is a very rare disease accounting for 0.06% of all bladder tumors. Owing to their rarity and symptomatic variability, preoperative diagnosis is often difficult. Case presentation A 70‐year‐old mal
Externí odkaz:
https://doaj.org/article/9f8f7893d06b46e09f4bc91f9b015b0a
Autor:
Hirofumi Kurose, Keisuke Komiya, Naoyuki Ogasawara, Kosuke Ueda, Katsuaki Chikui, Kiyoaki Nishihara, Makoto Nakiri, Mitsunori Matsuo, Shigetaka Suekane, Tsukasa Igawa
Publikováno v:
LUTS: Lower Urinary Tract Symptoms. 15:89-95
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1357a8c753a2ef8439d45d61359b791
https://doi.org/10.1111/luts.12474
https://doi.org/10.1111/luts.12474
Autor:
Kosuke Ueda, Naoyuki Ogasawara, Naoki Ito, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 6; Pages: 2417
Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various cancers treated with immune checkpoint inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ca23fd28891f3b17dc6fe84fd7005f
Autor:
Kosuke Ueda, Hirofumi Kurose, Makoto Nakiri, Katsuaki Chikui, Tsukasa Igawa, Shigetaka Suekane, Tasuku Hiroshige, Mitsunori Matsuo, Keiichiro Uemura, Kiyoaki Nishihara, Naoyuki Ogasawara
Publikováno v:
Japanese Journal of Clinical Oncology. 52:179-186
Objective Programmed cell death-1 antibody therapy has demonstrated improved progression-free survival and overall survival in patients with metastatic renal cell carcinoma. However, there are limited studies on biomarkers that can predict the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f9a702d3c4c222c30d058b8fe090902
https://doi.org/10.1093/jjco/hyab157
https://doi.org/10.1093/jjco/hyab157
Autor:
KOSUKE UEDA, SHIGETAKA SUEKANE, HIROFUMI KUROSE, NAOKI ITO, NAOYUKI OGASAWARA, TASUKU HIROSHIGE, KATSUAKI CHIKUI, KAZUHISA EJIMA, KEIICHIRO UEMURA, MAKOTO NAKIRI, KIYOAKI NISHIHARA, MITSUNORI MATSUO, TSUKASA IGAWA
Publikováno v:
Anticancer research. 42(9)
Immuno-oncology (IO) combination therapy has become the standard of treatment for advanced renal cell carcinoma (RCC). In this retrospective study, we compared the efficacy of first-line molecular targeted therapy (MTT), administered as monotherapy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa2bdc87fe0cf92d3a250d6b77785509
https://pubmed.ncbi.nlm.nih.gov/36039432
https://pubmed.ncbi.nlm.nih.gov/36039432
Autor:
Naoyuki Ogasawara, Makoto Nakiri, Hirofumi Kurose, Kosuke Ueda, Katsuaki Chikui, Kiyoaki Nishihara, Mitsunori Matsuo, Shigetaka Suekane, Yoshitaka Morimatsu, Kenta Murotani, Koichiro Muraki, Chikayuki Hattori, Etsuyo Ogo, Tatsuya Ishitake, Tsukasa Igawa
Publikováno v:
International journal of urology : official journal of the Japanese Urological AssociationREFERENCES.
To evaluate the effects of sarcopenia and excess visceral fat accumulation on early urinary function after I-125 low-dose-rate brachytherapy for prostate cancer.We retrospectively reviewed consecutive patients who underwent brachytherapy for prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af81a2a36eb8955f45511c8f1eb77d8b
https://pubmed.ncbi.nlm.nih.gov/36520921
https://pubmed.ncbi.nlm.nih.gov/36520921